CTLA4 and atherosclerosis: Similarly, another preclinical study on hypercholesterolemic ApoE3*Leiden mice showed that administration of anti-CTLA-4 increased vascular lesion size, whereas abatacept, a soluble CTLA-4Ig fusion protein, reduced atherosclerosis development [23].